Literature DB >> 24453654

Energy expenditure during gait in patients with mucopolysaccharidosis.

Marcos Almeida Matos1, André Prado1, Gustavo Schenkel1, Rosa Barreto2, Angelina Xavier Acosta2.   

Abstract

OBJECTIVE: The aim of this study is to evaluate energy expenditure in gait by mucopolysaccharidosis affected patients by means of a simple and adequate to the clinical environment methodology.
METHODS: A cross-sectional study was carried out comparing energy expenditure during gait in 19 patients suffering from mucopolysaccharidosis (MPS Group) with 19 asymptomatic control individuals (Control Group). Energy expenditure was measured in calories (cal) using a Polar telemetric watch (model FT7) during a 50 meter walk. Variables such as age, weight, height, body mass index (BMI), initial hart rate, final hart rate, and walking time, were recorded.
RESULTS: MPS Group showed a mean energy expenditure during gait of 2.84 cal (±1,01), versus 1.42 cal (±0,51), 100% higher than the Control Group; MPS also presented increased initial hart rate (22% higher), final hart rate (13% higher) and walking time (13% higher).
CONCLUSIONS: Energy expenditure during gait in MPS patients was two times higher than control individuals; the methodology used showed to be a promising alternative, also adequate to the standard clinical environment. Level of Evidence III, Cross-sectional Comparative Study.

Entities:  

Keywords:  Evaluation; Gait; Mucopolysaccharidosis I

Year:  2013        PMID: 24453654      PMCID: PMC3861965          DOI: 10.1590/S1413-78522013000200009

Source DB:  PubMed          Journal:  Acta Ortop Bras        ISSN: 1413-7852            Impact factor:   0.513


  16 in total

1.  High- or low- technology measurements of energy expenditure in clinical gait analysis?

Authors:  R Boyd; S Fatone; J Rodda; C Olesch; R Starr; E Cullis; D Gallagher; J B Carlin; G R Nattrass; K Graham
Journal:  Dev Med Child Neurol       Date:  1999-10       Impact factor: 5.449

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 3.  Management guidelines for mucopolysaccharidosis VI.

Authors:  Roberto Giugliani; Paul Harmatz; James E Wraith
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

4.  Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

5.  Reliability of a timed walk test in persons with acquired brain injury.

Authors:  Kurt A Mossberg
Journal:  Am J Phys Med Rehabil       Date:  2003-05       Impact factor: 2.159

Review 6.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

7.  Performance-based gait tests for acute stroke patients.

Authors:  Inácio Teixeira Cunha; Peter A C Lim; Helene Henson; Trilok Monga; Huma Qureshy; Elizabeth J Protas
Journal:  Am J Phys Med Rehabil       Date:  2002-11       Impact factor: 2.159

8.  The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease.

Authors:  L Cahalin; P Pappagianopoulos; S Prevost; J Wain; L Ginns
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

9.  Accuracy of polar S410 heart rate monitor to estimate energy cost of exercise.

Authors:  Scott E Crouter; Carolyn Albright; David R Bassett
Journal:  Med Sci Sports Exerc       Date:  2004-08       Impact factor: 5.411

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  2 in total

1.  FUNCTIONAL INDEPENDENCE OF PEDIATRIC PATIENTS WITH MUCOPOLYSACCHARIDOSES.

Authors:  Paloma Silva Lopes; Diógenes Pires Serra; Marcos Antônio Almeida Matos
Journal:  Acta Ortop Bras       Date:  2019 Jul-Aug       Impact factor: 0.513

2.  Applying the functional independence measure to the assessment of patients with mucopolysaccharidosis.

Authors:  Marcos Almeida Matos; Paloma Silva Lopes; Allan Rodrigues Corsini; Julia Rodi; Chin-To Fong
Journal:  Colomb Med (Cali)       Date:  2020-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.